Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable weight-loss and diabetes drugs. One thing hampering the GLP-1 drug boom is the fact that they're shots — not oral medications — which keeps some prospective patients from taking them. Lilly — which makes the diabetes drug Mounjaro and the weight-loss treatment Zepbound — reported positive Phase 3 trial results for the oral medication orforglipron.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
